Understanding how a specific immune response affects severe C. difficile infections
Role of Th17 in Severe and Recurrent C. difficile Infection
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-10873871
This study is looking at how certain immune cells might make Clostridioides difficile infections worse and why some treatments don’t work, while also exploring if fecal transplants can help protect against these infections, all to find better ways to help patients who are struggling with CDI.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-10873871 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Th17 immune cells in causing severe and recurrent Clostridioides difficile infections (CDI). The team aims to understand how these immune responses contribute to the severity of the infection and the reasons behind treatment failures. They will also explore how fecal microbiota transplants may help protect against these infections. By studying these mechanisms, the researchers hope to identify new immunotherapy approaches that could improve treatment outcomes for patients suffering from CDI.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced severe or recurrent C. difficile infections.
Not a fit: Patients who have not been diagnosed with C. difficile infections or those with mild cases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with severe and recurrent C. difficile infections.
How similar studies have performed: Previous research has shown that targeting immune responses can improve outcomes in similar infections, suggesting potential for success in this approach.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PETRI, WILLIAM A — UNIVERSITY OF VIRGINIA
- Study coordinator: PETRI, WILLIAM A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.